Research & Development

Research

Mochida's Research Center - targeting diabetes and obesity as its core fields and central nervous system (CNS) as another important field of study - is immersed in efforts to discover and synthesize promising low-molecular weight compounds, using state-of-the-art computer-screening, high-throughput screening, and other advanced methods.

Development

Mochida Pharmaceutical's product development pipelines offer lineups that will greatly enhance our major specialities: cardiovascular medicine, obstetrics and gynecology, dermatology, emergency medicine, and psychiatry. We remain ever committed to the efficient development of new and widely hoped-for therapeutic drugs, to be put to medical use as soon as is safely possible.

Pipeline

As of October 31,2016
Code Name Indications Formulation Stage Remarks
MD-0901 mesalazine Ulcerative colitis Oral approved Licensed-in from Shire Pharmaceuticals Group
[UK]
MJR-35 dienogest Adenomyosis Oral Filed Licensed-in from Jenapharm (a subsidiary of Bayer Pharma AG)
[Germany]
Functional dysmenorrhea Phase II
completed
LBEC0101 etanercept Rheumatoid arthritis Injection Phase III Biosimilar
Licensed-in from LG Life Sciences
[Korea]
AJG533 Elobixibat Chronic constipation Oral Phase III Co-development with EA Pharma
[Japan]
LBAL Adalimumab Rheumatoid arthritis Injection Phase III Biosimilar
Licensed-in from LG Life Sciences
[Korea]
RGB-10 Teriparatide Osteoporosis Injection Phase III Biosimilar
Licensed-in from Gedeon Richter
[Hungary]
[Medical device]
dMD-001 sodium alginate Articular cartilage lesion   Therapeutic exploratory study (Pilot study)